Generics and biosimilar medicines company Sandoz has trumpeted the launch of what it calls a ‘global roadmap to increase patient access to biologic medicines’.
The Act4Biosimilars Action Plan is part of the Act4Biosimilars initiative, founded by Sandoz and launched in 2022, and aims to increase global adoption to copycat biologics by at least 30% in at least 30 countries by 2030.
Sandoz is the generics and biosimilars business of Novartis (NOVN: VX), which the Swiss pharma giant plans to spin off later this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze